Volume | 77,988 |
|
|||||
News | - | ||||||
Day High | 20.32 | Low High |
|||||
Day Low | 20.00 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Fulgent Genetics Inc | FLGT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
20.03 | 20.00 | 20.32 | 20.10 | 20.03 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,217 | 77,988 | $ 20.14 | $ 1,570,556 | - | 19.88 - 44.09 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:44:31 | 8 | $ 19.75 | USD |
Fulgent Genetics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
598.08M | 29.78M | - | 289.21M | -167.83M | -5.63 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Fulgent Genetics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FLGT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 20.01 | 21.05 | 19.97 | 20.45 | 159,126 | 0.09 | 0.45% |
1 Month | 21.70 | 21.89 | 19.88 | 20.83 | 162,232 | -1.60 | -7.37% |
3 Months | 24.71 | 26.365 | 19.88 | 22.93 | 221,245 | -4.61 | -18.66% |
6 Months | 24.58 | 30.68 | 19.88 | 25.00 | 208,727 | -4.48 | -18.23% |
1 Year | 28.87 | 44.09 | 19.88 | 29.49 | 217,005 | -8.77 | -30.38% |
3 Years | 84.71 | 112.00 | 19.88 | 60.42 | 361,605 | -64.61 | -76.27% |
5 Years | 7.25 | 189.8899 | 4.712 | 59.68 | 509,578 | 12.85 | 177.24% |
Fulgent Genetics Description
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign. |